Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.750-0.800 for the period. The company issued revenue guidance of $3.0 billion-$3.1 billion.

Analysts Set New Price Targets

Several brokerages have recently commented on AMRX. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Barclays initiated coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.80.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $12.98 on Tuesday. The firm has a 50 day simple moving average of $12.29 and a two-hundred day simple moving average of $10.35. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $13.48. The company has a market cap of $4.08 billion, a P/E ratio of 649.32 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The company had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the sale, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 231,856 shares of company stock worth $2,743,724. Company insiders own 17.45% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Comerica Bank increased its stake in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares during the period. Focus Partners Wealth acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $42,000. Advisory Services Network LLC bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $50,000. Bellevue Group AG acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $79,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $105,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.